Robeco Institutional Asset Management B.V. Makes New $1.05 Million Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Robeco Institutional Asset Management B.V. purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 69,944 shares of the company's stock, valued at approximately $1,053,000. Robeco Institutional Asset Management B.V. owned 0.15% of Pacira BioSciences as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock worth $38,000 after purchasing an additional 932 shares during the period. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences in the 2nd quarter valued at $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences during the 2nd quarter valued at $50,000. nVerses Capital LLC boosted its stake in Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Natixis acquired a new stake in Pacira BioSciences in the first quarter worth $95,000. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Stock Up 1.5 %

Shares of NASDAQ PCRX traded up $0.26 during trading on Monday, hitting $17.50. The stock had a trading volume of 535,955 shares, compared to its average volume of 860,933. The firm has a fifty day moving average of $15.62 and a two-hundred day moving average of $20.93. The company has a market capitalization of $807.98 million, a PE ratio of -8.62 and a beta of 0.82. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 5.70. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on PCRX shares. Jefferies Financial Group upped their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, September 24th. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. HC Wainwright reduced their price objective on Pacira BioSciences from $57.00 to $39.00 and set a "buy" rating for the company in a research note on Monday, August 12th. Truist Financial lowered Pacira BioSciences from a "buy" rating to a "sell" rating and lowered their target price for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. Finally, Royal Bank of Canada lifted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $24.30.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.